A “Clear” Result Does Not Mean Zero Genetic Risk
Donner et al. (2018) analyzed over 100,000 dogs and found 152 disease-associated genetic variants distributed across both purebreds and mixed breeds — many in dogs whose owners had no idea their pet carried them. Modern genomic tests screen for these known variants using DNA microarray chips. They do not sequence the entire genome.
That distinction matters. A “clear” result means the tested variants were not found. It does not mean the dog has no genetic disease risk — only that the specific mutations currently identified by research are absent.
What current panels typically assess:
- Breed identification: ancestry composition based on reference breed databases
- Known disease variants: single-gene conditions with identified mutations (MDR1 drug sensitivity, von Willebrand disease, degenerative myelopathy, etc.)
- Carrier status: dogs carrying one copy of a recessive disease gene without being affected
- Physical trait markers: coat color, furnishing, body size genes
- Genetic diversity: inbreeding coefficient based on runs of homozygosity
For longevity planning, the health variant results are the most actionable. See genetic testing clinical ROI for a deeper analysis of testing value.
Platform Comparison
Embark (Breed + Health)
Price range: $150-250 Health variants tested: 350+ (as of 2025) Breed database: 350+ breeds Notable features:
- Largest health variant panel among direct-to-consumer platforms
- Provides inbreeding coefficient (COI) based on genetic data
- Includes ALT activity variant (relevant for liver enzyme interpretation)
- Relative finder feature connects genetically related dogs
- Cornell University research partnership validates genotyping accuracy
Strengths: Most comprehensive health panel, strong research backing, breed identification accuracy, inbreeding analysis Limitations: Higher price point, some health results require veterinary interpretation
Wisdom Panel (Premium)
Price range: $100-200 Health variants tested: 200+ (as of 2025) Breed database: 350+ breeds Notable features:
- Owned by Mars Veterinary (large database from decades of breed identification)
- Includes MDR1 drug sensitivity, cardiac disease genes, bleeding disorders
- Breed composition accuracy is strong for common breeds
- Lower price point makes it accessible for basic screening
Strengths: Affordable, established breed identification, good for basic health screening Limitations: Smaller health variant panel than Embark, less genetic diversity data
Breed-Specific Testing Panels
Price range: $50-150 per panel Scope: Focused on variants relevant to specific breeds Providers: Orthopedic Foundation for Animals (OFA), breed club-affiliated labs, university veterinary genetics labs
Use case: When you know the breed and need specific disease clearances (e.g., DM testing for German Shepherds, cardiac gene panels for Cavalier King Charles Spaniels, MDR1 for herding breeds) Strengths: Targeted, often accepted by breed registries, may test variants not on consumer panels Limitations: Narrow scope, requires knowing which tests are relevant for the breed
Which Results Actually Change What You Do
High-Impact Actionable Findings
- MDR1 mutation (ABCB1 gene). Dogs with one or two copies of this mutation are sensitive to ivermectin, loperamide, and certain chemotherapy drugs. Knowing this status prevents potentially fatal drug reactions. Common in herding breeds: Collies, Australian Shepherds, Shelties.
- Degenerative myelopathy (SOD1 gene). Two copies (at-risk status) indicates risk for this progressive spinal cord disease. Allows early mobility monitoring and intervention planning.
- Von Willebrand disease. Bleeding disorder variants inform surgical risk assessment. Essential to know before any planned surgery.
- Cardiac variants. DCM-associated genes in Dobermans, MMVD predisposition in Cavalier King Charles Spaniels — these inform cardiac monitoring frequency.
Moderate-Impact Findings
- Breed composition in mixed breeds. Knowing breed ancestry allows targeted condition screening. A dog with significant German Shepherd ancestry warrants hip dysplasia monitoring; Boxer ancestry increases cancer surveillance priority.
- Inbreeding coefficient. Higher COI is associated with reduced immune function and increased disease susceptibility. Dogs with high COI may benefit from more proactive health monitoring.
Low-Impact Findings (Often Over-Interpreted)
- “At risk” status for complex polygenic conditions. Many common diseases (hip dysplasia, cancer, epilepsy) involve many genes plus environmental factors. A single variant “at risk” result for these conditions changes absolute risk by a small amount and should not trigger panic.
- Carrier status for recessive conditions. Carriers are almost never clinically affected. This information is relevant for breeding decisions, not for the individual dog’s health management.
Practical Recommendations
- Test once, early in life. Genomic results do not change. Testing at 1-2 years old provides actionable information for the entire lifespan.
- Share results with your veterinarian. Genomic data is most valuable when integrated with clinical assessment. Your vet can prioritize screening based on identified risk variants.
- For mixed-breed dogs: Embark or Wisdom Panel Premium. Breed identification plus health screening provides the most value for dogs of unknown ancestry.
- For known purebreds: breed-specific panels plus a comprehensive consumer test. Breed-specific panels may test variants not on consumer platforms, while consumer tests provide the broader screen.
- Do not over-react to “at risk” findings for polygenic conditions. Discuss with your veterinarian what each finding means for actual clinical risk in the context of breed, age, and lifestyle.
What Genomic Tests Cannot Tell You
- Genomic tests identify known variants only. Many disease-causing mutations have not yet been discovered.
- Genetic risk is not genetic destiny. Environmental factors, nutrition, exercise, and preventive care all modulate genetic predispositions.
- Mixed-breed dogs may carry variants from multiple breed backgrounds, creating novel risk combinations that reference databases cannot fully predict.
- No current consumer platform provides a complete health prediction — they test what is known, which is a fraction of total genetic health influence.
Common Mistakes
- Treating genomic testing as a one-time “health guarantee.” Clear results do not mean the dog will never develop disease.
- Ignoring results because they seem complicated. Ask your veterinarian to prioritize which findings are actionable and which are informational.
- Breeding decisions based solely on one or two variant results without considering overall genetic diversity and breed health context.
- Purchasing the cheapest test and expecting comprehensive health screening. The variant panels differ significantly between platforms and price points.
Frequently Asked Questions
Which genomic test should I get for my dog?
For most owners, Embark Breed + Health provides the most comprehensive single test. If budget is a concern, Wisdom Panel Premium offers good breed identification and basic health screening at a lower price point. For known purebreds, consider breed-specific panels in addition to a consumer test.
Can genomic testing predict how long my dog will live?
No. Genomic testing identifies specific risk variants, not lifespan predictions. It helps guide targeted screening and preventive care, which can improve longevity outcomes, but it does not predict individual lifespan.
Is the MDR1 test worth getting for all dogs?
If your dog has any herding breed ancestry (even partial), MDR1 testing is essential — this variant can cause fatal drug reactions. For non-herding breeds, the risk is much lower but testing is still included in comprehensive panels.
How accurate is breed identification in mixed-breed dogs?
Both Embark and Wisdom Panel claim high accuracy for identifying breeds that constitute more than 5% of a dog’s ancestry, validated against known-parentage dogs. Accuracy decreases for very small contributions and for breeds not well-represented in reference databases.
Should I test my dog’s puppies?
If you are breeding, yes — for carrier status of breed-relevant diseases and to assess genetic diversity. If the dog is a pet, testing the individual dog is sufficient; puppy testing adds no additional information for that dog’s longevity planning.
Bottom Line
Canine genomic testing is a practical longevity tool when used correctly. It identifies specific disease risk variants, drug sensitivities, and breed-associated health predispositions that inform targeted screening and prevention strategies. For most dog owners, a comprehensive consumer test (Embark or Wisdom Panel Premium) provides useful health information at a reasonable cost. The key is integrating results with clinical veterinary care rather than treating them as standalone health predictions.